FDA peptide review could lead to new compounding boom

The FDA's advisory panel will decide Thursday whether to loosen compounding restrictions on seven peptides, potentially unlocking a $295bn market by 2033. Health Secretary RFK Jr., a peptide user and supporter, is pushing for relaxed manufacturing rules despite FDA scientists' safety concerns and lack of human efficacy data.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.